Communiqués Lipella Pharmaceuticals Inc.

Actions

LIPO

US53630L1008

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 27/06/2024			Varia. 5j.	Varia. 1 janv.
0,4497 ^USD	-4,52%		-30,17%	-55,91%

09/05	Lipella Pharmaceuticals Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
17/04	Lipella Pharmaceuticals Inc. nomme Jason Hafron et Pradeep Tyagi au conseil scientifique consultatif	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus	31/05	AQ
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	29/05	AQ
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b	21/05	AQ
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise	17/04	AQ
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024	05/04	AQ
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis	03/04	AQ
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease	07/03	AQ
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline	05/03	AQ
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference	20/02	AQ
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished	20/12	AQ
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease	10/11	PR
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules	25/10/23	PR
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules	24/10/23	PR
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus	23/10/23	AQ
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus	20/10/23	PR
Lipella Pharmaceuticals Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology	22/09/23	AQ
Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology	21/09/23	PR
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite	17/04/23	PR
Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent	05/04/23	PR
Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board	01/03/23	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Lipella Pharmaceuticals Inc.

Actions

LIPO

US53630L1008

Communiqués

Filtres